The purpose of this study was to evaluate the efficacy of highresolution axillary ultrasound (AU) in detecting the rate of recurrence after an egative sentinel node (SN) biopsy in patients with breast cancer and without additional axillary dissection.
INTRODUCTION
Breast cancersurgery continues to become moreconservative due to earlierd iagnosis through mammo-graphic screening, an increasing role of diagnostic ultrasound and magnetic resonance imaging. Ad evelopment of image-guided core-needle biopsy and sentinel lymph node biopsy area sa na lternative to conventional axillary dissection (1, 2).
The status of lymph nodes in the axilla is the most significant prognostic factor for survival in breast cancer patients. Ten-year survival rate of 85% has been reported in Finland, when the axillary lymph nodes areuninvolved, compared to 60-70% survival with metastasis in the axilla (3-6). The sentinel node (SN) is the first node that receives lymph fluid from the periareolar Sappey's plexus of the breast, as well as tumors of the breast. Lymphatic mapping with sentinel node (SN) biopsy has been proposed to provide accuratelymphatic staging with less morbidity than the diagnostic axillary dissection (2, 7). Therefore, SN biopsyhas replaced diagnostic axillary clearance in many breast surgery units.
Alow clinical axillary recurrence rate (2%) with a negative sentinel node biopsy,and without an additional axillary dissection, has been reported during the follow-up between one to three years (8-10).Usually the follow-up methods havei ncluded clinical examinations, annual mammography and questionnaires (7, [11] [12] . Axillary ultrasound combined with corebiopsy and aclinical examination is apowerful method in assessing axillarynodal status after therapy for advanced breast cancer (13) (14) (15) . Because SN biopsy is known to produce false-negative results in 5-10% of patients, we examined the usefulness of AU to detect the possible failures of SN biopsiesi na long-term follow-up study (13-49 months) .
MATERIALS AND METHODS

PATIENTS
Patients with clinical stageT1-2, N 0 breast cancers and radiologically unifocal tumors, weree nrolled for this prospective sentineln ode (SN) study.N ationwide screening mammography of women aged 50-59 years was started in Finland during January 1987 (6). In the present material, 58/196 breast cancers (30%) weref ound during mammographic screening. The mean age of the patients was 58 ± 13 years, and one-thirdofthe patients werepremenopausal. BetweenJanuary 2001 and December 2004, 196 patients with breast cancer wereo perated by using sentinel node technique. The diagnosis of breast cancer was confirmed preoperatively by fine-needle aspiration cytology (n =21), by stereotactic (n =147, Alpha RT Instrumentarium ® ,Helsinki, Finland) or by ultrasound-guided (n =28) core biopsies. If preoperative biopsiesw eren ondiagnostic (n =28), asurgical wire-guided biopsy was performed. The tumors werep alpable in 109 cases (56%) and nonpalpable in 87 cases (44%). The patient characteristics, operative parameters, histology,g rade of tumor,T NM-classification and survival rate werer ecorded in the SPSS program package software10.0 (SPSS Inc., Chicago, IL). The project plan was approved by the Ethical Committee of our hospital, and written consent was obtained from each patient.
TECHNIqUE OF LyMPHOSCINTIgRAPHy
Lymphoscintigraphy was performed one day prior to surgery.Four hours after asingle peritumoral injection (0.2 ml) of 80 to 100 MBq 99mTc-labeled human albumin microcolloid (Nanocoll ® , Sorin Biomedica Diagnosis, Saluggia, Italy) anterior and lateral planar views wereo btained using a gamma camera (Siemens Ecam + ,Erlangen, germany). The estimated location of sentinel nodes as well as the injection site of the tracer weremarked with apermanent pen on the skin (16) . The radioactive tracer injection was performedto the parenchymas urrounding the breast tumor under palpation control by an uclear medicine technologist. When the tumor was not palpable, tracer was injected under the subareolar tissue near the tumour area. If the tumour had been earlier removed, the injection was performed to both sides of the scar.Parasternal lymph nodes werepositive in lymphoscintigrams in 20 patients( 10%). The radioactive parasternal nodes werealso removed and histologicalanalysis was performed. Eight patients (40%) had metastasis in the removedp arasternal nodes. All patients with metastatic parasternal nodes received radiotherapy and chemotherapy.
SURgICAL METHODS
At least 10 minutes prior to skin incision, 1m lo fP atent Blue dye was injected intratumorally (Bleu PatenteV ® ; Laboratoireg euerbet, Aulnay-sous-Bois, France). The radioactive sentinel nodes wereh arvested using ag amma probe (Navigator ® gPS; AutosutureE uropean Services Center,S .A., France) and by searching for blue-staining lymphatic vessels and nodes. When the breast cancer diagnosis was confirmed, either conventional mastectomy (n =100) or breast-conserving surgery (n =96) was performed. The number of nodes, blue staining and radioactivity werec arefully recorded. When the sentineln ode was positive, usually at least ten or morea xillary nodes were removed for histological analysis.The mean operating time was 60 ±24min. The surgery was free of complications in 86% of patients.
HISTOLOgIC METHOD
We routinely used frozen section and conventional pathology to obtain am icroscopic diagnosis. All resected specimens and sentinel nodesweresent to thepathology laboratory for intraoperative diagnosis of frozen sectionand the determination of free margins. The sentineln odes were sliced into 1-1.5 mm thick sections and mounted on iced OCT (Sakura, Finetek, Europe, B.V., The Netherlands). Frozen sections from two levels werem ade from these slices; thesew eres tained with toluidine blue and viewed.T he remaining tissue was fixed in phosphate-buffered 10% formalin for H&E staining. The frozen sections werec onsidered positive for metastasis, if morphologically identifiable cancer cells weref ound in the lymph node. We did not perform immunostaining in frozen sections. If the sentinel nodes were cancerous, complete axillary dissection was carried out and all lymph nodes at levels Ia nd II were identified and embedded in paraffin for Hematoxylin&Eosin staining. In 7/196cases (3,6%) metastasis (3 micrometastasis, diameter between 0.2 and 2.0 mm), was found in the final histology in sentinel nodes, and axillary dissection was later carried out.
TECHNIqUE OF AxILLARyULTRASOUND (AU)
The patients, whose SNswerenegative during surgery,and an additional axillary clearance was not performed, were invited for AU during January 2005 (a median follow-up time from surgery was 31 months, range 13 -4 9m onths). The ultrasonographic assessment of axillary lymph nodes was based on the morphology,s hape and size. Al ymph node was considered pathologici ft he longitudinal to the transverse axis ratio was less than two, or if the thickness of the cortex wasmorethan 2mm (17) . Lymph nodes were categorized as suspicious for malignancy based on size >1.0 cm. Abscense of the hilum was also suggestive of malignancy (18) . If lymph nodes wereconsidered sonographically abnormal,a nu ltrasound-guided large coren eedle biopsy was carried out (15) . Three biopsies were carried out by 14 gauge needleand one small lesion by 16 gauge needle. An automated Bard Magnum ® biopsy instrument (Bard Inc., USA) was used and the biopsies wereundertaken using AU guidance. Axillas werescanned by 5-10 MHz (Aloka SSD 5000, Aloka Co. Ltd, Japan) or 7-14 MHz (Toshiba Aplio SSA-700A, Toshiba Medical systems Co., Japan) ultrasoundprobe.
Postoperative adjuvant therapies included radiotherapy in 128 patients (65%),c hemotherapy in 86 patients (44%) and hormonal therapy in 110p atients (57%). If axillary or sentinel nodes werei nvolved, the patients received postoperative radiotherapytothe breast area, to the axillary,as well as the supraclavicular and internal mammary fields.
RESULTS
Preoperative lymphoscintigraphy was performed in all patients eligible for SN biopsy(n=196), considering the SNs werevisualized on preoperative gamma camera scans in only 167 cases (85%, table1 ). The patients with negative lymphoscintigraphy (n =29) as well werenegative in Patent Blue® staining in 18 cases. Furthermoreneither blue or radioactive nodes werefound in 9.2% of cases, and all the patientswere operated by axillary clearance of lymph nodes. If the sentinel nodes werepositive either in lymphoscintigraphy or in Patent Blue ® staining, they weref ound during the operation in 177/196 cases (90%). When the sentineln odes werei dentified in preoperative lymphoscintigraphy (n =167), they weref ound in 163/167 cases (98%) during the operation. One node was removed in 83,t wo nodes in 42, and three or more positive nodes in 42 patients.
Metastasis in the SN was found in 29% of the patients (table 1). One patient had alocal recurrence of breast cancer in the mastectomy scar.Six patient developed distant metastasis (3 died) during the followup. One patient died (73 years old) during the followup due to coronary heart disease and cardiac insufficiency.T able 2presents the characteristics of breast cancers and some biological data of tumors.
We invited all patients with an egative SN and without axillary dissection, to AU in January 2005 (from 1to4yearspostoperatively). Fourpatientshad abnormal lymphn odes in theh igh-resolution AU. The corebiopsies revealed benign lymphadenopathy in two cases, scar formation in one case and lymphomatous involvement in one case. All coreb iopsies wereperformed without any complications.
DISCUSSION
The accurate performance of SN biopsy is essential in breast cancer surgery.M ost validated series of SN biopsyconfirm that the technique is falsely negative in 5-10% of node-positive cases (2, 7). Our ultrasound evaluation confirmed that SN biopsy is reliably for patients at least from one to four years of follow-up, due to no axillary recurrence being found. To our knowledge, AU has been utilized earlier only once in the evaluation of axillaryr ecurrence after the negative SN (19) . In the Study of Reisamer et al, no local or axillary recurrences occurred at am ean duration of follow-up for 22 ±6months (19) . Our results after am ean follow-up of 31 months support the earlier results. SN biopsy was feasible, accurate, and worked best with acombination of blue dye and radioisotope mapping.
Axillary ultrasound and fine-needle aspiration or corebiopsies have been used many years to evaluate the breast and regional nodes in the follow-up of breast cancer adjuvant treatment (14, 18, (21) (22) . Ultrasound can identify abnormal nodes in patients presenting with breast cancer and axillary metastasis (13, 22) . In all axillary enlarged nodes, approximately 65% arem alignant in breast cancer,t his can be confirmed with ultrasound-guided corebiopsy (17) .The corebiopsy of axilla has proven to be asafe and reliable method in axilla (15) . However,anegative postsurgical AU or physicalexamination does not always predict pathologic node status, and these tests may have limited value at least after neoadjuvant chemotherapy in locally advancedb reast cancer (23) . As well postoperative adjuvant radiotherapy and chemotherapy may cause temporary disappearance of metastasis in axilla, thereforethe follow-up time has to be long enough to give acorrect diagnosis. Previous researchers have followed the patients only from one to two years, which might be too short time (20, 24) . Other researchers have used clinical examinations, blood chemistry and annual mammography to follow-up axillary recurrence (8) (9) (10) (11) (12) . The studies confirmed that axillary recurrence was very rarea fter a negative sentinel node biopsy (about 0.25-1%). The longest follow-up time was 7y ears (median followup 38 months) reporting 37/953 (4%) axillary metastasis (7). Every tenthwoman in Finland suffers from breast cancer during her life. The incidence of breast cancer in Finland has increased from 30/100 000 female inhabitants in 1965 to 80/100 000 in 2000 (5). Under the impact of mammography and ultrasound, breast cancers tend to be nowadays smaller,g rowing slower, and they areperhaps less aggressive than previously (25) .The overall 5-year survival rate of breast cancer in Finland is about 85%. In our surgical unit, thanks to the SN technique, about 60% of women with stage Io rI Ib reast cancer weres pared axillary dissection and related complications. Axillary sonography is operator-dependent,and sonography does not demonstrate all of the axillary lymph nodes. For example, micrometastatic disease may be undetected on axillary ultrasound. Despitet he limitations, axillary ultrasound is av aluable tool in the quality control of sentinel node technique. Postoperative axillary ultrasonography is relevant at the starting phase of sentinel node biopsies to confirm the quality of surgery. The cost may be too high in the experiencedsurgical centers due to very few positive findings of AU.
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